BRPI0414107A - produtos intermediários para a preparação de hìbridos de oxazolidinon-quinolona - Google Patents

produtos intermediários para a preparação de hìbridos de oxazolidinon-quinolona

Info

Publication number
BRPI0414107A
BRPI0414107A BRPI0414107-5A BRPI0414107A BRPI0414107A BR PI0414107 A BRPI0414107 A BR PI0414107A BR PI0414107 A BRPI0414107 A BR PI0414107A BR PI0414107 A BRPI0414107 A BR PI0414107A
Authority
BR
Brazil
Prior art keywords
oxazolidinon
preparation
intermediates
quinolone
hybrids
Prior art date
Application number
BRPI0414107-5A
Other languages
English (en)
Inventor
Christian Hubschwerlen
Jean-Luc Specklin
Jean Philippe Surivet
Daniel K Baeschlin
Original Assignee
Morphochem Ag Komb Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphochem Ag Komb Chemie filed Critical Morphochem Ag Komb Chemie
Publication of BRPI0414107A publication Critical patent/BRPI0414107A/pt
Publication of BRPI0414107B1 publication Critical patent/BRPI0414107B1/pt
Publication of BRPI0414107B8 publication Critical patent/BRPI0414107B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"PRODUTOS INTERMEDIáRIOS PARA A PREPARAçãO DE HìBRIDOS DE OXAZOLIDINON-QUINOLONA". A presente invenção descreve produtos intermediários (ZP) para uma síntese nova e eficiente de compostos, nos quais os farmacóforos de quinolona e oxazolidinona estão ligados uns com os outros através de um ligante quimicamente estável.
BRPI0414107A 2003-09-03 2004-09-03 produtos intermediários para a preparação de híbridos de oxazolidinon-quinolona BRPI0414107B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10340485.6 2003-09-03
DE2003140485 DE10340485B4 (de) 2003-09-03 2003-09-03 Verfahren zur Herstellung von Oxazolidinon-Chinolon Hybriden
PCT/EP2004/009858 WO2005023801A1 (de) 2003-09-03 2004-09-03 Zwischenprodukte für die herstellung von oxazolidinon-chinolon hybriden

Publications (3)

Publication Number Publication Date
BRPI0414107A true BRPI0414107A (pt) 2007-04-27
BRPI0414107B1 BRPI0414107B1 (pt) 2018-07-03
BRPI0414107B8 BRPI0414107B8 (pt) 2021-05-25

Family

ID=34258351

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414107A BRPI0414107B8 (pt) 2003-09-03 2004-09-03 produtos intermediários para a preparação de híbridos de oxazolidinon-quinolona

Country Status (16)

Country Link
US (2) US7557214B2 (pt)
EP (2) EP2374806B1 (pt)
JP (1) JP4742039B2 (pt)
KR (1) KR101211025B1 (pt)
CN (1) CN100467466C (pt)
AU (1) AU2004270379B2 (pt)
BR (1) BRPI0414107B8 (pt)
CA (1) CA2537345C (pt)
DE (1) DE10340485B4 (pt)
ES (1) ES2509868T3 (pt)
IL (2) IL173407A0 (pt)
MX (1) MXPA06002366A (pt)
NZ (1) NZ545491A (pt)
RU (1) RU2373203C2 (pt)
WO (1) WO2005023801A1 (pt)
ZA (1) ZA200601178B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
MXPA05011654A (es) 2003-04-30 2005-12-15 Morphochem Ag Komb Chemie Uso de antibioticos hibridos de oxazolidinona-quinolina para el tratamiento del antrax y de otras infecciones.
DE10340485B4 (de) * 2003-09-03 2015-05-13 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Verfahren zur Herstellung von Oxazolidinon-Chinolon Hybriden
US8158797B2 (en) 2003-12-18 2012-04-17 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Oxazolidinone-quinolone hybrid antibiotics
ES2310299T5 (es) 2003-12-18 2014-02-10 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibióticos híbridos a base de oxazolidinona-quinolona
US8124623B2 (en) 2006-11-10 2012-02-28 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
CL2007003332A1 (es) 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
US20080176860A1 (en) * 2007-01-19 2008-07-24 Lutz Weber Pyridin-2-one compounds
EP3003289B1 (en) 2013-05-28 2019-02-20 Morphochem Aktiengesellschaft für kombinatorische Chemie Administration of oxazolidinone-quinolone hybrid antibacterials
RU2675847C2 (ru) 2013-05-28 2018-12-25 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций
CN108059624A (zh) * 2016-11-08 2018-05-22 上海医药工业研究院 用于制备咔哒唑胺关键中间体的制备方法
US10087171B2 (en) 2016-12-19 2018-10-02 Actelion Pharmaceuticals Ltd Crystalline forms of cadazolid

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840956A (en) 1986-02-18 1989-06-20 Warner-Lambert Company Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
NZ222047A (en) 1986-10-08 1991-01-29 Bristol Myers Co Quinoline - or naphthyridine - carboxylic acid anti-bacterial agents
JPH0269478A (ja) 1988-09-05 1990-03-08 Sagami Chem Res Center キノロンカルボン酸誘導体
US5491139A (en) 1988-10-24 1996-02-13 The Procter & Gamble Company Antimicrobial quinolonyl lactams
DE69019859T2 (de) 1989-03-30 1995-10-05 Wakunaga Seiyaku Kk Chinolon-Derivate und deren Salze, Verfahren zu deren Herstellung und diese enthaltende antibakterielle Wirkstoffe.
EP0610265B1 (en) 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
US5221676A (en) 1992-02-06 1993-06-22 Warner-Lambert Company 7-substituted quinolones and naphthyridones as antibacterial agents
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
ES2200439T3 (es) 1995-09-22 2004-03-01 Wakunaga Pharmaceutical Co., Ltd. Intermedios para utilizar en la preparacion de nuevos derivados del acido piridonocarboxilico o sus sales.
DE19601265A1 (de) 1996-01-16 1997-07-17 Bayer Ag 2-Oxo- und 2-Thio-1,2-dihydrochinolinyl-oxazolidinone
GB9702213D0 (en) 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
DE19633480A1 (de) 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
CA2318969A1 (en) * 1998-01-23 1999-07-29 Mikhail F. Gordeev Oxazolidinone combinatorial libraries, compositions and methods of preparation
TW572757B (en) * 1998-08-24 2004-01-21 Bristol Myers Squibb Co Novel isoxazolinone antibacterial agents
KR100324621B1 (ko) 1999-04-27 2002-02-27 박호군 퀴놀론이 치환된 옥사졸리디논 유도체 및 그의 제조 방법과 항균제로서의 용도
CN1367780A (zh) 1999-07-28 2002-09-04 法玛西雅厄普约翰美国公司 噁唑烷酮类化合物、其制备方法及其应用
US6518285B2 (en) * 1999-12-21 2003-02-11 Ortho Mcneil Pharmaceutical, Inc. Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials
EP1349853B1 (en) 2000-12-21 2006-03-08 Pharmacia & Upjohn Company LLC Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
ES2186550B2 (es) 2001-06-27 2003-11-16 Vita Lab Nuevos derivados de oxazolidinonas como antibacterianos.
WO2003031443A1 (en) * 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
WO2003031441A1 (en) 2001-10-04 2003-04-17 Morphochen Aktiengesellschaft Für Kombinatorische Chemie Multiple action compounds
EP2292615A1 (en) 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
US20040132764A1 (en) * 2002-10-23 2004-07-08 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Antibiotics for the treatment of infections in acidic environments
EP1594852A1 (en) * 2003-02-07 2005-11-16 Ranbaxy Laboratories, Ltd. Oxazolidinone derivatives as antimicrobials
MXPA05011654A (es) * 2003-04-30 2005-12-15 Morphochem Ag Komb Chemie Uso de antibioticos hibridos de oxazolidinona-quinolina para el tratamiento del antrax y de otras infecciones.
DE10340485B4 (de) * 2003-09-03 2015-05-13 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Verfahren zur Herstellung von Oxazolidinon-Chinolon Hybriden
US8158797B2 (en) * 2003-12-18 2012-04-17 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Oxazolidinone-quinolone hybrid antibiotics
ES2310299T5 (es) * 2003-12-18 2014-02-10 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibióticos híbridos a base de oxazolidinona-quinolona
AR054608A1 (es) 2005-08-08 2007-06-27 Actelion Pharmaceuticals Ltd Derivados de oxazolidinona enlazados a quinolonas como antibacterianos
CL2007003232A1 (es) 2006-11-10 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.
CL2007003332A1 (es) 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
PL2296651T3 (pl) 2008-05-09 2012-12-31 Actelion Pharmaceuticals Ltd Pochodne 5-hydroksymetylooksazolidyn-2-onu do leczenia bakteryjnych chorób jelitowych

Also Published As

Publication number Publication date
WO2005023801A1 (de) 2005-03-17
CA2537345A1 (en) 2005-03-17
IL173407A0 (en) 2006-06-11
BRPI0414107B1 (pt) 2018-07-03
NZ545491A (en) 2009-12-24
US20070004769A1 (en) 2007-01-04
EP2374806B1 (de) 2016-11-02
BRPI0414107B8 (pt) 2021-05-25
JP2007504262A (ja) 2007-03-01
IL205706A0 (en) 2011-08-01
HK1083848A1 (en) 2006-07-14
CN100467466C (zh) 2009-03-11
EP1660489A1 (de) 2006-05-31
RU2373203C2 (ru) 2009-11-20
IL205706A (en) 2013-06-27
ZA200601178B (en) 2007-04-25
AU2004270379B2 (en) 2011-03-31
US8124772B2 (en) 2012-02-28
DE10340485B4 (de) 2015-05-13
EP2374806A1 (de) 2011-10-12
US7557214B2 (en) 2009-07-07
CN1845923A (zh) 2006-10-11
ES2509868T3 (es) 2014-10-20
KR20060121849A (ko) 2006-11-29
JP4742039B2 (ja) 2011-08-10
DE10340485A1 (de) 2005-05-12
AU2004270379A1 (en) 2005-03-17
MXPA06002366A (es) 2006-06-20
RU2006110535A (ru) 2007-10-10
EP1660489B1 (de) 2014-07-02
KR101211025B1 (ko) 2012-12-11
US20090306389A1 (en) 2009-12-10
CA2537345C (en) 2013-01-29

Similar Documents

Publication Publication Date Title
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
CO5611065A2 (es) Difluorometiltiazolilcarboxanilidas
EA201000050A1 (ru) Замещенные бициклолактамные соединения
TNSN05007A1 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof.
CY1112011T1 (el) Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
SE0200920D0 (sv) Novel compounds
SE0300480D0 (sv) Novel compounds
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
AU2005240213A8 (en) Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
EA200801560A1 (ru) Бифенилкарбоксамиды
TW200638930A (en) Acetylene derivatives
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
MXPA05013751A (es) Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales.
BRPI0414107B8 (pt) produtos intermediários para a preparação de híbridos de oxazolidinon-quinolona
HRP20090474T1 (hr) Postupak i intermedijeri za sintezu kaspofungina
TW200745122A (en) New compounds I
MXPA05008960A (es) Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.
GB0229081D0 (en) Multifunctional cationic photoinitiators, their preparation and use
TW200740781A (en) Novel compounds
TW200745039A (en) Isotopically substituted pantoprazole
GB0327323D0 (en) Novel pharmaceuticals
SE0202693D0 (sv) Compounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 413/12, 263/20; A61P 31/00

Ipc: C07D 413/12 (2011.01), C07D 263/20 (2011.01), A61P

Free format text: "PARA: INT. CL. C07D 413/12, 263/20

Ipc: C07D 413/12 (2011.01), C07D 263/20 (2011.01), A61P

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/09/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2846 DE 22-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.